gsk-2816126 and Glioma

gsk-2816126 has been researched along with Glioma* in 1 studies

Other Studies

1 other study(ies) available for gsk-2816126 and Glioma

ArticleYear
Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
    Experimental brain research, 2023, Volume: 241, Issue:10

    Glioma is the most common malignant brain tumor, and its behavior is closely related to the presence of glioma stem cells (GSCs). We found that the enhancer of zeste homolog 2 (EZH2) is highly expressed in glioma and that its expression is correlated with the prognosis of glioblastoma multiforme (GBM) in two databases: The Cancer Genome Atlas and the Chinese Glioma Genome Atlas. Additionally, EZH2 is known to regulate the stemness-associated gene expression, proliferation, and invasion ability of GSCs, which may be achieved through the activation of the STAT3 and Notch1 pathways. Furthermore, we demonstrated the effect of the EZH2-specific inhibitor GSK126 on GSCs; these results not only corroborate our hypothesis, but also provide a potential novel treatment approach for glioma.

    Topics: Antineoplastic Agents; Asian People; Brain Neoplasms; Enhancer of Zeste Homolog 2 Protein; Glioma; Humans; Neoplastic Stem Cells

2023